Hormonal
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular events (MACE) by approximately 14% in patients with type 2 diabetes, independent of glucose-lowering effects.
If you have Type 2 Diabetes and are at risk for heart disease, GLP-1 medications (like semaglutide or liraglutide) are proven to significantly lower your risk of heart attack, stroke, and cardiovascular death. These benefits exist even beyond just lowering blood sugar. While injections can cause stomach upset, starting with a low dose and increasing slowly usually manages this. Oral options are also available for some drugs.
Strong evidence of a cardiovascular risk reduction benefit of GLP- 1 RAs in people with T2D has accumulated with data from large cardiovascular outcomes trials (CVOT) collectively showing a significant relative risk reduction of 14% for the 3-component MACE composite outcome (major cardiovascular adverse events, comprising cardiovascular death, myocardial infarction, and non- fatal stroke) (Sattar et al., 2021).
Why this rating
Based on large cardiovascular outcomes trials (CVOT) and systematic reviews/meta-analyses of randomized trials.
Source
Glucagon‐like peptide‐1 receptor agonists to expand the healthy lifespan: Current and future potentials
Frederik Flindt Kreiner et al. · Aging Cell · 2023
DOI 10.1111/acel.13818
More from this paper
- GLP-1 RAs promote significant weight loss (up to 18-21% in clinical trials) by acting on central brain regions to modify food preferences, reduce appetite, and increase satiety.Strong
- GLP-1 RAs show potential to slow the progression of neurodegenerative diseases, including Alzheimer's and Parkinson's, by reducing neuroinflammation and potentially acting as neuroprotective agents.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →